206 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이영열-
dc.date.accessioned2018-01-31T08:21:44Z-
dc.date.available2018-01-31T08:21:44Z-
dc.date.issued2011-02-
dc.identifier.citationINVESTIGATIONAL NEW DRUGS, v. 29, Page. 154-160en_US
dc.identifier.isbn10.1007/s10637-009-9320-y-
dc.identifier.issn0167-6997-
dc.identifier.issn1573-0646-
dc.identifier.urihttps://link.springer.com/article/10.1007/s10637-009-9320-y-
dc.description.abstractBackground: We investigated response rates to and toxicities of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Patients and Methods: Patients with recurrent or refractory diffuse large B-cell lymphoma or mantle cell lymphoma (DLBCL) were eligible for enrollment in this study. Treatment consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, ifosfamide 2,000 mg/m(2) i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, patients could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles. Results: Twenty-seven eligible patients were evaluated for toxicity and response. The median age of the patients was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 neutropenia occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 thrombocytopenia occurred in 14% and 16% of the cycles, respectively. Two patients (2%) experienced febrile neutropenia, while seven patients (26%) proceeded to HDC-ASCT. Conclusions: GIDOX is an active salvage regimen for aggressive B-cell NHL and can be tolerated by patients with acceptable toxicity.en_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.subjectGemcitabineen_US
dc.subjectSalvage therapyen_US
dc.subjectNon-Hodgkin's lymphomaen_US
dc.titleSalvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trialen_US
dc.typeArticleen_US
dc.relation.volume29-
dc.relation.page154-160-
dc.relation.journalINVESTIGATIONAL NEW DRUGS-
dc.contributor.googleauthorPark, Byeong-Bae-
dc.contributor.googleauthorKim, Won Seog-
dc.contributor.googleauthorEom, Hyeon Seok-
dc.contributor.googleauthorKim, Jin Seok-
dc.contributor.googleauthorLee, Young Yiul-
dc.contributor.googleauthorOh, Suk Joong-
dc.contributor.googleauthorLee, Dae Ho-
dc.contributor.googleauthorSuh, Cheolwon-
dc.relation.code2011204426-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidleeyy-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE